NGNE — Neurogene Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1404644 ·
Last close
$23.10
Market Cap
$478.19M
52W High
$43.66
52W Low
$15.93
ADV30
333,315
Next earnings
2026-11-09
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -32,376,000 -29,023,000 377,901,000 78,942,000 23,107,000
Jun 2026 0 — -36,670,000 -34,488,000 244,364,000 112,485,000 27,231,000
Mar 2026 0 — -33,349,000 -30,934,000 263,141,000 124,161,000 25,358,000
Dec 2025 0 — -27,529,000 -24,735,000 288,604,000 103,845,000 23,717,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-96,454,000
Investing CF
$-84,041,000
Financing CF
$188,432,000
CapEx
$-1,078,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.96
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-447,094,000
Inventory
—
Receivables
$242,000
ST Investments
$280,776,000
EBIT TTM
$-119,179,000
Pretax Income TTM
$-119,180,000
Interest Exp TTM
$1,000
Analysts
8

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -103,328,000 -90,351,000 288,604,000 23,717,000 264,887,000 -77,173,000
Dec 2024 925,000 -82,605,000 -75,144,000 335,730,000 25,355,000 310,375,000 -70,603,000
Dec 2023 0 -55,583,000 -36,317,000 222,573,000 36,549,000 186,024,000 -51,422,000
Dec 2022 0 -56,517,000 -55,189,000 109,265,000 255,004,000 -145,739,000 -52,824,000

TTM Snapshot

Revenues TTM
$1,101,000
NetIncome TTM
$-111,110,000
OpCashFlow TTM
—
Assets (Latest)
$244,364,000
Forward EPS
$-5.03

Max Pain — expiry 2027-12-17 (volume-derived — Yahoo OI feed degraded)

max pain strike: $35.00 · spot: $23.14 · call volume: 63 · put volume: 30
Expected Move to 2027-12-17: ±$17.00 (73.47%) — implied range $6.14 – $40.14 · ATM straddle on $25.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
IMMP IMMUTEP Ltd $480.43M $3.26 —
BLSM BlossomHill Therapeutics, Inc. $480.91M $15.13 —
MNPR Monopar Therapeutics $481.56M $71.06 —
AMRN AMARIN CORP PLC\UK $473.82M $11.27 —
KMDA KAMADA LTD $470.92M $8.16 —

News headlines (Yahoo Finance, 1h cache)

Does Neurogene (NGNE) Have the Potential to Rally 203.28% as Wall Street Analysts Expect?
2026-11-11 20:19 · Yahoo
Neurogene: Q3 Earnings Snapshot
2026-11-09 12:35 · Yahoo
Neurogene Reports Third Quarter 2026 Financial Results and Highlights Recent Updates
2026-11-09 12:30 · Yahoo
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-11-05 21:01 · Yahoo
Neurogene to Participate in Upcoming Investor Conferences
2026-11-03 12:30 · Yahoo
Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome
2026-10-27 11:30 · Yahoo
Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress
2026-10-20 11:30 · Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-05 20:01 · Yahoo
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 11:30 · Yahoo
Neurogene Inc. Announces Pricing of $125 Million Public Offering
2026-07-01 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.